The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.
The company also inked a deal with an investment bank to publicly offer from time to time up to $4.2 million of its stock.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 63 percent year over year.
Memorial Hermann's outreach sites will transfer testing to Quest's Houston lab and the firm will also provide management services for the system's 21 hospital labs.
Blueprint provides 3,900 targeted single-gene and more than 200 panel tests covering 14 medical specialties, leveraging NGS and bioinformatics methods.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
Of the 39 deals included in the analysis, only three exceeded $100 million in value, with the rest having significantly smaller price tags or prices that were not disclosed.
The oncology division of Human Longevity performs next-generation sequencing services for pharmaceutical customers and generated $10 million in revenue in 2019.
Provista is developing and commercializing the Videssa blood test for breast cancer, which has been clinically validated for early detection.
The new firm will offer target enrichment assays for clinical NGS testing and develop library preparation kits for clinical tests on Illumina's sequencing platform.